Investors & Media

Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome

Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo First study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent   Olezarsen demonstrated a favorable

Read more
You are now leaving to visit